A Study to Compare Bempegaldesleukin (BEMPEG: NKTR-214) Combined With Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI Alone in Participants With Previously Untreated Kidney Cancer That is Advanced or Has Spread

Local Institution - 0026, Buenos Aires

Local Institution - 0024, San Juan

Local Institution - 0025, Mar del Plata

Local Institution - 0009, New York

Local Institution - 0079, Marseille

Local Institution - 0048, Mexico City

Local Institution - 0045, Hanover

Local Institution, Nashville

Local Institution, Louisville

Local Institution - 0050, Zapopan

Local Institution - 0042, Essen

Local Institution - 0001, St Louis

Local Institution - 0049, Monterrey

Local Institution - 0005, Springdale

Local Institution - 0055, Querétaro

Local Institution - 0044, Munich

Local Institution - 0041, Nuremberg

Local Institution - 0046, Würzburg

Local Institution, Portland

Local Institution - 0007, Seattle

Local Institution - 0059, Moscow

Local Institution - 0052, Moscow

Local Institution - 0087, Moscow

Local Institution - 0058, Saint Petersburg

Local Institution - 0051, Novosibirsk

Local Institution - 0085, Omsk

Local Institution - 0032, Barretos

Local Institution - 0014, Houston

Local Institution - 0075, Río Cuarto

Local Institution - 0030, Belo Horizonte

Local Institution - 0035, Curitiba

Local Institution - 0028, Porto Alegre

Local Institution - 0036, Santa Cruz do Sul

Local Institution - 0029, São José do Rio Preto

Local Institution - 0056, Edmonton

Local Institution - 0015, Vancouver

Local Institution - 0022, St. John's

Local Institution - 0008, Toronto

Local Institution - 0040, Jena